Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients

BACKGROUND: Resistance to immune checkpoint blockade and targeted therapy in melanoma patients is currently one of the major clinical challenges. With the approval of talimogene laherparepvec (T-VEC), oncolytic viruses are now in clinical practice for locally advanced or non-resectable melanoma. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Fröhlich, Anne, Niebel, Dennis, Fietz, Simon, Egger, Eva, Buchner, Andrea, Sirokay, Judith, Landsberg, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183503/
https://www.ncbi.nlm.nih.gov/pubmed/32052079
http://dx.doi.org/10.1007/s00262-020-02487-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183503/
https://www.ncbi.nlm.nih.gov/pubmed/32052079
http://dx.doi.org/10.1007/s00262-020-02487-x

Ejemplares similares